Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Zoetis
ZTS
$31.1B
| $253M | 0.19% |
1,908,278
-292,484
| -13% | -$36.3M |
|
102
Etsy
ETSY
$7.29B
| $252M | 0.19% |
5,681,327
-1,585,253
| -22% | -$75.5M |
|
103
General Mills
GIS
$20.2B
| $250M | 0.19% |
4,676,212
-808,772
| -15% | -$42.6M |
|
104
Intel
INTC
$493B
| $250M | 0.19% |
4,181,894
+4,000,700
| +2,208% | +$224M |
|
105
Markel Group
MKL
$22.8B
| $247M | 0.19% |
216,281
+3,431
| +2% | +$3.91M |
|
106
Equinor
EQNR
$97.2B
| $246M | 0.19% |
12,358,764
+1,294,403
| +12% | +$24.5M |
|
|
OPTU
107
Optimum Communications Inc
OPTU
$324M
| $244M | 0.19% |
8,931,600
-586,000
| -6% | -$16.2M |
|
|
AIV
108
Aimco
AIV
$376M
| $244M | 0.19% |
35,471,864
-6,653,881
| -16% | -$47M |
|
109
Spotify
SPOT
$103B
| $244M | 0.19% |
1,628,220
+154,900
| +11% | +$21.3M |
|
110
GoDaddy
GDDY
$11.5B
| $243M | 0.19% |
3,578,000
+530,100
| +17% | +$35M |
|
111
Baidu
BIDU
$35.9B
| $242M | 0.19% |
1,916,977
+1,195,277
| +166% | +$136M |
|
|
AMTD
112
DELISTED
TD Ameritrade Holding Corp
AMTD
| $242M | 0.19% |
4,864,505
+2,289,479
| +89% | +$99.2M |
|
113
Netflix
NFLX
$311B
| $241M | 0.19% |
7,456,000
+973,000
| +15% | +$28.8M |
|
|
AZPN
114
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $238M | 0.18% |
1,964,003
-413,900
| -17% | -$50.1M |
|
115
Invitation Homes
INVH
$17.7B
| $236M | 0.18% |
7,886,883
+2,159,500
| +38% | +$64.7M |
|
116
Cogent Communications
CCOI
$554M
| $236M | 0.18% |
3,588,366
-27,334
| -0.8% | -$1.65M |
|
117
Allison Transmission
ALSN
$10.3B
| $235M | 0.18% |
4,873,319
+1,032,059
| +27% | +$48M |
|
118
Xcel Energy
XEL
$48.5B
| $235M | 0.18% |
3,706,369
-1,538,361
| -29% | -$96.2M |
|
119
UDR
UDR
$12B
| $231M | 0.18% |
4,956,408
-2,603,840
| -34% | -$125M |
|
120
Essex Property Trust
ESS
$18.2B
| $231M | 0.18% |
768,354
-149,546
| -16% | -$47.2M |
|
121
American Tower
AMT
$79B
| $229M | 0.18% |
995,854
-527,970
| -35% | -$115M |
|
122
Qorvo
QRVO
$8.53B
| $227M | 0.17% |
1,951,754
+956,848
| +96% | +$92.5M |
|
123
MSCI
MSCI
$40.8B
| $226M | 0.17% |
877,211
-164,477
| -16% | -$40.1M |
|
124
Alphabet (Google) Class A
GOOGL
$4.2T
| $224M | 0.17% |
3,340,960
+2,722,000
| +440% | +$176M |
|
125
SiriusXM
SIRI
$9.61B
| $222M | 0.17% |
3,100,770
+1,855,157
| +149% | +$125M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.